Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

Spanish Lung Cancer Group676 enrolled

Overview

The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab. A standard anonymous data collection form will be used to collect data and to analyze it. Patients with advanced Non-Small Cell Lung Cancer previously treated and included in the SPANISH expanded access programme of nivolumab.

This study will help to understand the efficacy of Nivolumab in the real world setting within the SPANISH expanded access programme. The main objective of this study is to evaluate nivolumab efficacy in terms of Overall Survival (OS), Progression Free Survival (PFS), Overall Response Rate (ORR) and safety in the clinical practice. The efficacy variables will be assessed for patients (squamous vs non-squamous) who received second line therapies or third lines and subsequent lines and also, long responders will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

676

Conditions

Non Small Cell Lung Cancer

Interventions

Nivolumab 10 MG/MLDRUG

nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Squamous or Non-Squamous, non small cell lung cancer (NSCLC), Stage IIIb/IV (histologically or cytologically confirmed), relapsed after 1 prior platinum-based systemic treatment and who received treatment within the SPANISH expanded access programme of nivolumab (EAP) 2. Alive patients must have signed and dated an IRB/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care Exclusion Criteria: 1. Alive patients who do not want to sign and date an IRB/IEC-approved written informed consent form 2. Patients who were accepted in the EAP but do not receive treatment

Locations (61)

Outcomes

Primary Outcomes

Progression Free survival

time from inclusion to progression

Time frame: At 12 months

Secondary Outcomes

Overall Response rate

Percentage of patient reaching a complete, partial or stable disease

Time frame: At 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Hospital Virgen de los Lirios

Alcoy, Alicante, Spain

Hospital de Elche

Elche, Alicante, Spain

Hospital Universitario de Vinalopó

Elche, Alicante, Spain

Hospital General Universitario de Elda

Elda, Alicante, Spain

H. Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital de Mataró

Mataró, Barcelona, Spain

Corporació Sanitaria Parc Taulí

Sabadell, Barcelona, Spain

Consorci Sanitari de Terrassa

Terrassa, Barcelona, Spain

Hospital Universitari Mútua de Terrassa

Terrassa, Barcelona, Spain

Hospital de Galdakao

Galdakao, Bizkaia, Spain

...and 51 more locations